Diabetic maculopathy: Diagnosis and treatment;Diabetische Makulopathie: Diagnose und Behandlung

Ophthalmologe

Volumn 107, Issue 8, 2010, Pages 773-788

  Gelisken, F ^a   Ziemssen, F ^a  

^a UNIVERSITY OF TÜBINGEN   (Germany)

Author keywords

Anti VEGF therapy; Diabetic retinopathy; HbA1c (glycohemoglobin); Laser photocoagulation; Macula edema

Indexed keywords

ANGIOGENESIS INHIBITOR; ANTIINFLAMMATORY AGENT; APTAMER; BEVACIZUMAB; GLYCOSYLATED HEMOGLOBIN; HEMOGLOBIN A1C PROTEIN, HUMAN; MONOCLONAL ANTIBODY; PEGAPTANIB; RANIBIZUMAB; TRIAMCINOLONE ACETONIDE; VASCULOTROPIN A;

ARTICLE; BLOOD; COMPARATIVE STUDY; DIABETIC RETINOPATHY; DRUG ANTAGONISM; FLUORESCENCE ANGIOGRAPHY; HUMAN; INTRAVITREAL DRUG ADMINISTRATION; ISCHEMIA; LASER COAGULATION; METABOLISM; METHODOLOGY; MULTIMODALITY CANCER THERAPY; OPHTHALMOSCOPY; OPTICAL COHERENCE TOMOGRAPHY; RANDOMIZED CONTROLLED TRIAL (TOPIC); RETINA DETACHMENT; RETINA MACULA EDEMA;

ANGIOGENESIS INHIBITORS; ANTI-INFLAMMATORY AGENTS; ANTIBODIES, MONOCLONAL; APTAMERS, NUCLEOTIDE; COMBINED MODALITY THERAPY; DIABETIC RETINOPATHY; FLUORESCEIN ANGIOGRAPHY; HEMOGLOBIN A, GLYCOSYLATED; HUMANS; INTRAVITREAL INJECTIONS; ISCHEMIA; LASER COAGULATION; MACULAR EDEMA; OPHTHALMOSCOPY; RANDOMIZED CONTROLLED TRIALS AS TOPIC; RETINAL DETACHMENT; TOMOGRAPHY, OPTICAL COHERENCE; TRIAMCINOLONE ACETONIDE; VASCULAR ENDOTHELIAL GROWTH FACTOR A;

EID: 77955849499     PISSN: 0941293X     EISSN: None     Source Type: Journal    
DOI: 10.1007/s00347-010-2202-z     Document Type: Article

References (43)

1. Aiello LP, Avery RL, Arrigg PG et al (1994) Vascular endothelial growth factor in ocular fluid of patients with diabetic retinopathy and other retinal disorders. N Engl J Med 331: 1480-1487.
2. Bhavsar AR, Ip MS, Glassman AR, DRCRnet and the SCORE Study Groups (2007) The risk of endophthalmitis following intravitreal triamcinolone acetonide injection in the DRCRnet and SCORE clinical trials. Am J Ophthalmol 144: 454-456.
3. Biester S, Ziemssen F, Ulrich Bartz-Schmidt K, Gelisken F (2009) Is intravitreal bevacizumab treatment effective in diffuse diabetic macular edema? Graefes Arch Clin Exp Ophthalmol 247: 1575-1577.
4. Bolz M, Schmidt-Erfurth U, Deak G et al (2009) Optical coherence tomographic hyperreflective foci: a morphologic sign of lipid extravasation in diabetic macular edema. Ophthalmology 116: 914-920.
5. Bresnick HB (1983) Diabetic maculopathy. A critical review highlighting diffuse macular edema. Ophthalmology 90: 1301-1317.
6. Browning DJ, Glassman AR, Aiello LP et al (2008) Optical coherence tomography measurements and analysis methods in optical coherence tomography studies of diabetic macular edema. Ophthalmology 115: 1366-1371.
7. Brucker AJ, Qin H, Antoszyk AN et al (2009) Observational study of the development of diabetic macular edema following panretinal (scatter) photocoagulation given in 1 or 4 sittings. Arch Ophthalmol 127: 132-140.
8. Chung EJ, Roh MI, Kwon OW, Koh HJ (2008) Effects of macular ischemia on the outcome of intravitreal bevacizumab therapy for diabetic macular edema. Retina 28: 957-963.
9. Cunningham ET Jr, Adamis AP, Altaweel M et al (2005) A phase II randomized double-masked trial of pegaptanib, an antivascular endothelial growth factor aptamer, for diabetic macular edema. Ophthalmology 112: 1747-1757.
10. Diabetic Retinopathy Clinical Research Network (2008) A randomized trial comparing intravitreal triamcinolone acetonide and focal/grid photocoagulation for diabetic macular edema. Ophthalmology 115: 1447-1449.
11. Diabetic Retinopathy Clinical Research Network (2010) Randomized trial evaluating ranibizumab plus prompt or deferred laser or triamcinolone plus prompt laser for diabetic macular edema. Ophthalmology 117(6): 1064-1077, DOI 10. 1016/j. ophtha. 2010. 02. 031.
12. Early Treatment Diabetic Retinopathy Study Research Group (1985) Photocoagulation for diabetic macular edema. Report number 1. Arch Ophthalmol 103: 1796-1806.
13. Ejaz S (2008) Importance of pericytes and mechanisms of pericyte loss during diabetes retinopathy. Diabetes Obes Metab 10: 53-63.
14. Engelmann K, on behalf of the RESOLVE study group (2009) Safety and efficacy of ranibizumab treatment in patients with diabetic macular oedema: 12-months results of the RESOLVE study. Diabetologia [Suppl 1] 52: S31.
15. Forooghian F, Stetson PF, Meyer SA et al (2010) Relationship between photoreceptor outer segment length and visual acuity in diabetic macular edema. Retina 30: 63-70.
16. Funatsu H, Noma H, Mimura T et al (2009) Association of vitreous inflammatory factors with diabetic macular edema. Ophthalmology 116: 73-79.
17. Hammes HP, Bertram B, Bornfeld N et al (2004) Diagnostik, Therapie und Verlaufskontrolle der diabetischen Retinopathie und Makulopathie. In: Scherbaum WA, Kiess W (Hrsg) Evidenzbasierte Leitlinien der DDG, aktualisierte Version. Deutsche Diabetes-Gesellschaft, Bochum, www. deutsche-diabetes-gesellschaft. de.
18. Hanefeld M, Schönauer M, Forst T (2010) Blutzucker-Senkung und kardiovaskulärer Vorteil: Was wissen wir heute? Dtsch Med Wochenschr 135: 301-307.
19. Hartnett EM, Tinkham N, Paynter L et al (2009) Aqueous vascular endothelial growth factor as a predictor of macular thickening following cataract surgery in patients with diabetes mellitus. Am J Ophthalmol 148: 895-901.
20. Helbig H, Kellner U, Bornfeld N, Foerster MH (1997) Long-term vision follow-up after vitrectomy in diabetic retinopathy. Ophthalmologe 94: 268-272.
21. Hörle S, Grüner F, Kroll P (2002) Epidemiologie diabetischer Erblindungen - eine Übersicht. Klin Monatsbl Augenheilk 219: 777-784.
22. Kaji Y, Usui T, Ishida S et al (2007) Inhibition of diabetic leucostasis and blood-retinal barrier breakdown with a soluble form of a receptor for advanced glycation end products. Invest Ophthalmol Vis Sci 48: 858-865.
23. Kim BY, Smith SD, Kaiser PK (2006) Optical coherence tomographic patterns of diabetic macular edema. Am J Ophthalmol 142: 405-412.
24. Klein R, Klein BE, Moss SE et al (1984) The Wisconsin epidemiologic study of diabetic retinopathy. IV. Diabetic macula edema. Ophthalmology 91: 1464-1474.
25. Krumpazky HG, Lüdtke R, Mickler A et al (1999) Blindness incidence in Germany. Ophthalmologica 213: 176-182.
26. Kumagai K, Furukawa M, Ogino N (2009) Long-term follow-up of vitrectomy for diffuse nontractional diabetic macular edema. Retina 29: 464-472.
27. Lee CM, Olk RJ (1983) Modified grid laser photocoagulation for diffuse diabetic macular edema: long term results. Ophthalmology 90: 1301-1317.
28. Massin P, Duguid G, Erginay A et al (2003) Optical coherence tomography for evaluating diabetic macular edema before and after vitrectomy. Am J Ophthalmol 135: 169-177.
29. Matsuoka M, Ogata N, Minamino K, Matsumura M (2007) Leukostasis and pigment epithelium-derived factor in rat models of diabetic retinopathy. Mol Vis 13: 1058-1065.
30. Nguyen QD, Shah SM, Heier JS et al (2009) Primary end point (six months) results of the ranibizumab for edema of the macula in diabetes (READ-2) study. Ophthalmology 116: 2175-2181.
31. Nicholson BP, Schachat AP (2010) A review of clinical trials of anti-VEGF agents for diabetic retinopathy. Graefes Arch Clin Exp Ophthalmol 248(7): 915-930.
32. Parravano M, Menchini F, Virgili G (2009) Antiangiogenic therapy with anti-vascular endothelial growth factor modalities for diabetic macular oedema. Cochrane Database Syst Rev 7: CD007419.
33. Poulaki V, Qin W, Joussen AM et al (2002) Acute intensive insulin therapy exacerbates diabetic blood-retinal barrier breakdown via hypoxic-inducable factor 1-alpha and VEGF. J Clin Invest 109: 805-815.
34. Schernthaner G (2010) Diabetes and cardiovascular disease: is intensive glucose control beneficial or deadly? Lessons from ACCORD, ADVANCE, VADT, UKPDS, PROactive and NICE-SUGAR. Wien Med Wochenschr 160: 8-19.
35. Shah AS, Chen SH (2010) Cataract surgery and diabetes. Curr Opin Ophthalmol 21: 4-9.
36. Shweiki D, Neeman M, Itin A, Keshet E (1995) Induction of vascular endothelial growth factor expression by hypoxia and by glucose deficiency in multicell spheroids: implications for tumor angiogenesis. Proc Natl Acad Sci USA 92: 768-772.
37. Szaflik JP, Wysocki T, Kowalski M et al (2008) An association between vascular endothelial growth factor gene promoter polymorphisms and diabetic retinopathy. Graefes Arch Clin Exp Ophthalmol 246: 39-43.
38. Takamura Y, Kubo E, Akagi Y (2009) Analysis of the effect of intravitreal bevacizumab injection on diabetic macular edema after cataract surgery. Ophthalmology 116: 1151-1157.
39. Trautner C, Haastert B, Richter B et al (2003) Incidence of blindness in Southern Germany due to glaucoma and degenerative conditions. Invest Ophthalmol Vis Sci 44: 1031-1034.
40. Wang Y, Ng MC, Lee SC et al (2004) Epidemiology of diabetic retinopathy and macular oedema: a systematic review. Eye 18: 963-983.
41. Yokoi M, Yamigishi S, Takeuchi M et al (2007) Positive correlation between vitreous levels of advanced glycation end products and vascular endothelial growth factor in patients with diabetic retinopathy sufficiently treated with photocoagulation. Br J Ophthalmol 91: 397-398.
42. Ziemssen F (2008) Therapie der diabetischen Retinopathie. In: Bartz-Schmidt KU (Hrsg) Intravitreale Pharmakotherapie. Schattauer, Stuttgart.
43. Ziemssen F, Bartz-Schmidt KU, Grisanti (2006) (Side) effects of VEGF inhibition. Ophthalmologe 103: 484-492.